Peanut (Ara h 15) IgE

If you have ever wondered whether your body sees peanut as a threat, this is the kind of test that tries to answer that question one protein at a time. Ara h 15 is one of many individual peanut proteins (called components) that an allergy test can measure, and it sits at the very edge of what current research has actually studied.

Most of what is known about peanut blood testing comes from work on a different peanut protein called Ara h 2, which is the workhorse of modern peanut allergy diagnosis. Ara h 15 specifically has not been studied in published clinical research, so this test is best thought of as exploratory rather than a clear yes-or-no on peanut allergy.

What the Test Actually Measures

This is a blood test for IgE (immunoglobulin E), a type of antibody your immune system makes when it tags something as dangerous. When IgE specifically recognizes a peanut protein and latches onto immune cells called mast cells and basophils, it sets the stage for the rapid release of chemicals that cause allergic reactions.

In peanut-allergic people, IgE-producing cells are concentrated in the gastrointestinal tract, where they class-switch and release antibodies into the bloodstream. The blood level of any single peanut-component IgE, including Ara h 15, reflects whether your immune system has built antibodies against that particular protein. It does not, on its own, tell you whether you will react to eating peanut.

Where Ara h 15 Sits in the Evidence

This is the most important thing to know upfront. Across the available clinical research on peanut allergy diagnosis, severity, and treatment, none of the studies report data on Ara h 15 IgE. The peanut components that have been validated in human studies are Ara h 1, 2, 3, 6, 8, and 9.

That means Ara h 15 IgE is currently a research and exploratory marker. There are no published sensitivity or specificity numbers for it, no validated cutoffs that separate allergy from tolerance, and no outcome studies linking it to reaction risk. A result should be interpreted alongside a much broader picture, not in isolation.

Sensitization Versus Clinical Allergy

One of the most important ideas in peanut testing is that sensitization and allergy are not the same thing. Sensitization means your blood contains IgE against a peanut protein. Allergy means you actually react when you eat peanut. A population-based study of children found that only about 22% of those sensitized to peanut had true clinical allergy on a supervised food challenge.

This is why a positive component-IgE result, on its own, can mislead. Many people carry peanut-specific IgE without symptoms, and treating sensitization as a diagnosis can lead to unnecessary avoidance, anxiety, and missed nutritional opportunities. Any unexpected positive result on a peanut component should be interpreted by an allergist who can integrate it with your history.

What Higher Levels of Studied Peanut Components Mean

For the peanut components that have been studied, higher IgE levels generally track with a higher probability of true allergy and, on average, lower thresholds for reacting to small amounts. In a large infant cohort, Ara h 2 IgE at a cutoff of 0.1 kUA/L (a unit for very small antibody concentrations) gave roughly 94% sensitivity and 98% specificity for peanut allergy in that specific infant screening population. In broader populations using the standard 0.35 kUA/L cutoff, pooled sensitivity is around 83 to 86% and specificity around 84%. In adult challenge studies, Ara h 2 and Ara h 6 IgE performed similarly well.

Higher peanut-specific IgE has also been linked to higher anaphylaxis risk during supervised oral food challenges. A study of over 2,000 challenges found that increasing specific IgE levels to the trigger food were associated with a higher likelihood of anaphylactic symptoms. Whether Ara h 15 IgE follows any of these patterns is unknown, since no studies have measured it in this context.

Severity Is Not Fully Predicted by Any Single Number

Even for the best-studied peanut components, a single IgE value cannot reliably tell you how severe your next reaction will be. The quality of IgE (its specific activity, the diversity of peanut proteins it recognizes, and its ability to actually activate immune cells) matters more than the raw concentration. Cellular tests like the basophil activation test outperform IgE quantification alone for spotting people at highest risk of severe reactions.

This is not a contradiction of the earlier point. Higher IgE on average means higher risk, but there is so much individual variation that no number reliably predicts a personal worst-case reaction. Treat any peanut IgE result as one piece of a larger puzzle, not as a verdict on how dangerous peanut is for you.

How This Differs From a Standard Peanut Allergy Workup

A traditional peanut allergy workup uses whole-peanut IgE plus a skin prick test. These are highly sensitive (around 95 to 97%) but have low specificity (around 38 to 46%), so they tend to overdiagnose allergy when used alone. Component testing, especially Ara h 2 IgE, was developed to add specificity and reduce unnecessary food challenges.

Within component testing, Ara h 2 (and often Ara h 6) carry most of the diagnostic weight. Ara h 8 is a PR-10 protein related to birch pollen and typically reflects pollen cross-reactivity, often producing only mild oral allergy syndrome rather than systemic peanut reactions. Ara h 9 is different: it is a non-specific lipid transfer protein that cross-reacts with similar proteins in other plant foods such as peach, and in Mediterranean populations it can be associated with severe systemic reactions including bronchospasm. So a positive Ara h 8 is generally reassuring, while a positive Ara h 9 needs careful interpretation in clinical context. Ara h 15 falls outside this validated set entirely, which is why interpretation has to be cautious.

Tracking Levels Over Time

For people with established peanut allergy, longitudinal studies show that peanut and Ara h 2 IgE often decrease in children who naturally outgrow the allergy, while higher or rising levels predict persistence. In one cohort, about one third of infant peanut allergies resolved by age 10, and falling Ara h 2 IgE plus rising IgG4-to-IgE ratios accompanied that resolution.

For an exploratory marker like Ara h 15, the value of retesting comes from building your own personal trend line. A reasonable approach is to establish a baseline, retest in 3 to 6 months if you are making changes (such as supervised peanut introduction guided by an allergist or undergoing immunotherapy), and at least annually thereafter. Pair this with the more validated tests (whole-peanut IgE, Ara h 2 IgE) so you can interpret movement in context. The clinical meaning of trends in Ara h 15 specifically has not been established.

When Results Can Be Misleading

Several things can distort the picture this test gives you. The most important is that a positive result does not equal an allergic reaction risk, especially for an unstudied component.

• Cross-reactivity: IgE that recognizes one plant protein can sometimes bind to similar proteins from unrelated foods or pollens. A positive peanut component result might reflect sensitization driven by something else entirely.
• Total IgE context: People with very high overall IgE (from eczema, asthma, or parasitic exposure) tend to show more positive results across many allergens, including some that are not clinically meaningful.
• Lab platform differences: Different assays for specific IgE can produce different numbers for the same sample, so comparing results across labs requires caution.
• No validated cutoff: Because Ara h 15 has not been studied clinically, there is no number that has been shown to separate allergic from tolerant individuals.

What to Do With an Unexpected Result

If your Ara h 15 IgE comes back positive and you have no history of peanut reactions, do not start avoiding peanut on the basis of this number alone. The next step is to order or compare a more validated test, particularly Ara h 2 IgE, alongside whole-peanut IgE. If those are also positive and you have any history suggestive of reactions, an allergist visit is the right move.

An allergist can integrate your symptoms, family history, and the full pattern of component results. In selected cases, a basophil activation test or a supervised oral food challenge gives a far clearer answer than serology alone. If your standard peanut tests are negative and only Ara h 15 is positive, the result is unlikely to change clinical decisions given the current absence of outcome data, but it is reasonable to discuss with an allergist whether further evaluation makes sense.

Putting It Together

The honest framing for this test is that it offers an exploratory window into one specific peanut protein your immune system might recognize, in a research area that is still maturing. It is not a stand-in for an established peanut allergy diagnosis. For people with known or suspected peanut allergy, the bulk of the actionable information still comes from Ara h 2 IgE, whole-peanut IgE, skin testing, and, when needed, supervised food challenge.